K
Kohei Kaku
Researcher at Kawasaki Medical School
Publications - 347
Citations - 7993
Kohei Kaku is an academic researcher from Kawasaki Medical School. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 44, co-authored 311 publications receiving 6921 citations. Previous affiliations of Kohei Kaku include Kawasaki University of Medical Welfare.
Papers
More filters
Journal ArticleDOI
Longer HSD11B2 CA-repeat in impaired glucose tolerance and type 2 diabetes.
Tomoatsu Mune,Tetsuya Suwa,Hiroyuki Morita,Yukinori Isomura,Nobuki Takada,Yoritsuna Yamamoto,Makoto Hayashi,Noriyoshi Yamakita,Akihiko Sasaki,Noriyuki Takeda,Jun Takeda,Perrin C. White,Kohei Kaku +12 more
TL;DR: In this paper, the association of HSD11B2 variant with glucose homeostasis was investigated, with significant linear trends between the repeat length and the phenotype fraction, and the total CA-repeat length was negatively correlated with fasting insulin and HOMA-β.
Journal ArticleDOI
Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial.
TL;DR: To determine the efficacy and safety of adding liraglutide to three different insulin regimens in Japanese patients with type 2 diabetes mellitus, a large number of them have type 1 diabetes.
Journal ArticleDOI
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
Yasuo Terauchi,Hisataka Fujiwara,Yuji Kurihara,Hideki Suganami,Masahiro Tamura,Masayuki Senda,Ryoji Gunji,Kohei Kaku +7 more
TL;DR: The aim of the present study was to evaluate the safety and efficacy of tofogliflozin add‐on to glucagon‐like peptide‐1 (GLP‐1) receptor agonist monotherapy.
Journal ArticleDOI
Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes.
TL;DR: Type 2 diabetes was associated with increased RLP-chol in plasma and atherogenic RLP, and in nondiabetes, apo E2/2 contributes to increased plasma RLP -chol and atheogenic RLP.
Journal ArticleDOI
Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis
Takashi Kadowaki,Fumiko Yamamoto,Yusuke Taneda,Yusuke Naito,Douglas Clark,Søren S Lund,Tomoo Okamura,Kohei Kaku,Kohei Kaku +8 more
TL;DR: The cardiovascular and kidney safety of glucose-lowering drugs is a key concern in type 2 diabetes (T2D) patients as discussed by the authors, and the authors evaluated cardiorenal outcomes with glucose lowering drugs in Asian patients.